Technical Secrets – Flex Pharma Inc (NASDAQ: FLKS)

U.S. stock benchmarks ended near session lows Wednesday as the Federal Reserve accomplished its second increase to benchmark interest rates in 2018, as predictable, but signaled a slightly more aggressive plan to tighten monetary policy this year than had formerly been projected.

The rate increase also had the effect of narrowing a closely watched gap between rates of two-year and 10-year Treasury notes, which has recently been one of a strong predictor of recessions.

The S&P 500 fell 11.22 points, or 0.40%, at 2,775.63, with only one of the benchmark’s 11 sectors finishing in positive territory. The consumer-discretionary sector closed 0.1% higher but losses were led by a 0.4% drop in energy and consumer staples. Meanwhile, telecommunications tumbled 4.5%, predominantly on the back of a drop in shares of AT&T Inc. and Verizon Communications Inc, but that sector represents just 1.8% of the S&P 500’s total weight.

Meanwhile, the Dow Jones Industrial Average slumped 119.53 points, or 0.47%, to 25,201.20, dragged to session lows by a decline in Boeing Co. and Caterpillar Inc. both closing down by nearly 2%.

The Nasdaq Composite Index meanwhile, shed 8.09 points, or 0.11%, at 7,695.70; the technology-laden benchmark had set an intraday record 7,748.96 before paring those gains.

The Federal Reserve voted to raise its benchmark federal-funds rate by a quarter percentage point to a range of 1.75% to 2%. Eight of 15 Fed officials now expect at least four rate hikes will be needed this year, up from seven at the March meeting.

In corporate news, AT&T shares tumbled by 6%, representing its leading percentage fall since Nov. 5, 2008, following a federal judge’s Tuesday ruling that paved the way for the $85.4 billion merger with Time Warner Inc. The deal also assisted to deliver a boost to a number of media-related stocks, counting shares of 21st Century Fox Inc. and Walt Disney. [MarketWatch]

Stock to Watch: Flex Pharma Inc (NASDAQ: FLKS)

On Wednesday, Shares of Flex Pharma Inc (NASDAQ: FLKS) -75.12% and ended its trading session at $1.04. The company saw 2,796,596 shares trade hands over the course of the day. Given that its average daily volume over the 30 days has been 74.45K shares a day, this signifies a pretty noteworthy change over the norm.

Technical Analysis:

The analysts, on average, are forecasting a $17.00 price target, but the individual stock is already up -61.19% from its recent lows. However, the stock is trading at -88.42% as compared to recent highs. Leading up to this report, we have seen a -72.19% return in the stock price over the last 30 days and a -82.01% return over the past 3 months. Since the starting of the calendar year, the stock’s performance is recorded at -70.20%.

The stock price recently practiced a 5-day change of -74.38% with 0.47 as average true range (ATR). FLKS has a beta of 2.83 and RSI is 15.71.

Introduction to Net Income & Its Uses in Most Important Indicators:

Income is money received by an individual or business in exchange for supplying a good or service or through investing capital. Income is consumed to fuel day-to-day expenditures. In businesses, income can refer to a company’s remaining revenues after all expenses and taxes have been paid. In this case, it is also known as “earnings”. Most forms of income are subject to taxation.

However, Net income (NI) is a corporation’s total earnings (or profit); net income is computed by taking revenues and subtracting the costs of doing business such as depreciation, interest, taxes and other expenses. This number appears on a company’s income statement and is an important measure of how profitable the company is over a period of time.

Role of Net Income in Calculating EPS:

Businesses use net income to calculate their earnings per share (EPS). Business analysts often refer to net income to as the bottom line, since it is listed at the bottom of the income statement. In the United Kingdom, NI is known as profit attributable to shareholders. To know the company’s net income – refer to this link: Flex Pharma Inc (NASDAQ: FLKS) is a stock with 17.66M shares outstanding. As the earnings per share (EPS) formula is stated as earnings available to common shareholders divided by number of common stock shares outstanding, therefore its diluted EPS is calculated to be -1.97 (ttm). EPS is an indicator of company profit because the more earnings a company can generate per share, the more valuable each share is to shareholders.

A key aspect of EPS that’s often overlooked is the capital that is required to generate the earnings (net income) in the calculation. Two companies could generate the same EPS number, but one could do so with less equity (investment) – that company would be more efficient at using its capital to generate income and, all other things being equal would be a “better” company. Shareholders also need to be aware of earnings manipulation that will affect the quality of the earnings number. It is important not to rely on any one financial measure, but to use it in conjunction with statement analysis and other measures.

Role of EPS in Calculating Price to Earnings Ratio (P/E):

Earnings per share are generally pondered to be the single most essential variable in determining a share’s price. It is also a key component used to calculate the price-to-earnings valuation (P/E) ratio.

Analysts also use the price-to-earnings (P/E) ratio for stock valuation, which is calculated as market price per share ($1.04) divided by EPS (-1.97). The P/E ratio calculates how expensive a stock price is relative to the earnings produced per share. For example, if the P/E ratio of a stock is 20 times earnings, an analyst compares that P/E ratio to other companies in the same industry and to the ratio for the broader market.

Analysts’ Recommendation to Consider:

Analysts have a mean recommendation of 1.80 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range).

Disclaimer: Any news, report, research, and analysis published on are only for information purposes. Stocks Market Cap (SMC) makes sure to keep the information up to date and correct, but we didn’t suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. Information in this release is fact checked and produced by competent editors of Stocks Market Cap; however, human error can exist.

Chad Pitman

Chad Pitman

I am Chad Pitman and I focus on breaking news stories and ensuring we (“Stocks Market Cap”) offer timely reporting on some of the most recent stories released through market wires about “Emerging Stocks”. I have formerly spent over 3 years as a trader in U.S. Stock Market and is now semi-stepped down. I work on a full time basis for specializing in quicker moving active shares with a short term view on investment opportunities and trends.

Leave a Reply

Your email address will not be published. Required fields are marked *